I hear you Drano. But, to play the devil's advocate, I think the skeptic can listen to this presentation and say : no BOD or uplisting update, no biomarker results, and cohort 7 was delayed due to the protocol change.

For me as a long term holder, i am very excited to hear K has done so well so far. This has always been in essence a very simple long term investment for me, and everything I heard in the conference especially about K is great news to me.